Pharmaceutical Company to Invest $46M In Major Manufacturing Facility In Mid-Hudson Region

In what is a significant investment in the Hudson Valley Region’s economy, Gov. Kathy Hochul announced this week that Garonit Pharmaceutical, Inc., a global manufacturer of antiseptic products and health care solutions, will establish a state-of-the-art, 200,000-square-foot pharmaceutical manufacturing facility in New Windsor, Orange County.

With a $46.1 million investment, the facility will become the world’s largest chlorhexidine gluconate manufacturing operation, producing antiseptic products essential for surgical disinfection and infection prevention in hospitals worldwide.

New York State is supporting this project with $3.8 million, including up to $3.5 million through the Excelsior Jobs Program and a $300,000 Mid-Hudson Regional Economic Development Council capital grant. The project marks a major milestone in New York’s strategy to grow its life sciences sector and expand domestic pharmaceutical manufacturing.

“New York is leading the way in reshoring pharmaceutical manufacturing, strengthening supply chains and creating high-quality jobs — and Garonit Pharmaceutical’s decision to invest in Orange County is proof of that progress,” Governor Hochul said. “This world-class facility will produce essential antiseptic products used in surgical and world-class facility will produce essential antiseptic products used in surgical and hospital settings around the globe, further positioning our state as a leader in the life sciences sector. With this investment, we are not only creating good-paying jobs but also reaffirming that New York is where innovation and opportunity meet.”

BCW President & CEO Marsha Gordon, who is Co-Chair of the Mid-Hudson Regional Economic Development Council said, “The Garonit Pharmaceutical facility represents a transformative opportunity for Orange County and demonstrates the impact of strategic regional planning. This investment will create meaningful employment opportunities for our residents while advancing our region as a destination for pharmaceutical manufacturing. The comprehensive workforce development partnership with SUNY Orange ensures that local residents will be prepared to participate in this growing industry and benefit from the career opportunities it provides.”

The new facility, strategically located near Stewart International Airport, will serve as the world’s largest chlorhexidine gluconate manufacturing operation and will manufacture antiseptic products, including both ANDA and NDA formulations that are subject to full U.S. Food and Drug Administration approval.

Construction is scheduled to begin in Q1 2026, with production operations anticipated to start in January 2027. The project will create an estimated 100 to 150 construction jobs during the build phase, and the 100 full-time pharmaceutical positions will include production, quality assurance, warehouse, R&D, administration and logistics, management, and sales roles.